Maxim Group analyst Michael Okunewitch maintained a Buy rating on HCW Biologics (HCWB – Research Report) yesterday and set a price target of $4.00. The company’s shares opened today at $1.38.
Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, Mediwound, and Longeveron. According to TipRanks, Okunewitch has an average return of -28.1% and a 16.28% success rate on recommended stocks.
Currently, the analyst consensus on HCW Biologics is a Moderate Buy with an average price target of $6.00, representing a 334.78% upside. In a report released on March 29, JonesTrading also maintained a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
HCWB market cap is currently $47.73M and has a P/E ratio of -3.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCW Biologics Inc is a preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases. It is developing HCW9218 as an injectable immunotherapeutic for patients with solid tumors.
Read More on HCWB:
